Gemcitabine hydrochloride is a novel synthetic difluoronucleoside antimetabolic antitumor drug approved by the US Food and Drug Administration (FDA) for first-line treatment of non-small cell lung cancer and pancreatic cancer.
Gemcitabine hydrochloride is a new generation of anti-metabolites, which is a cell cycle specific drug, mainly acting on DNA synthesis phase, namely S phase cells. Under certain conditions, it can also prevent the progression of G1 phase to S phase, and it has strong anticancer activity against non-small cell lung cancer (NSCLC). Foreign studies have shown that gemcitabine hydrochloride alone has an effective rate of 18% ~ 35% in the treatment of NSCLC. Combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC), the effective rate was 41.7%. Carboplatin has an effective rate of 16% for advanced NSCLC, which is similar to cisplatin, but has low toxicity, especially in digestive tract reactions, bone marrow suppression, kidney and peripheral nerves. Combined with carboplatin, it has coordination and addition effect, and can produce higher curative effect.
Usage: It is suitable for the treatment of inoperable advanced or metastatic pancreatic cancer, local progressive or metastatic non-small cell lung cancer, and the treatment of medium and advanced non-small cell lung cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.
November 9, 2021 7:12 am
December 31, 9999
Shijiazhuang City, Hebei Province, China
You must log in or register a new account in order to contact the publisher